AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11778187 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave heating and bandaging treatment
Number of subjects: 27
Study 11778187 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy volunteers)
Number of subjects: 27
Study 9234031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) supplementation (1 g per day for two weeks)
Number of subjects: 8
Study 9234031 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 8
Study 8384948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (2.5 MJ)
Number of subjects: 0
Study 3941213 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY‐046, 400 mg/day orally
Number of subjects: 12
Study 3941213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30125761 — intervention group
Group type: EXPERIMENTAL
Intervention: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks (ddAC)
Number of subjects: 664
Study 30125761 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks (TAC)
Number of subjects: 664
Study 26649909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB) with 30 mL ropivacaine 0.75% at t0 and 30 mL saline at t60
Number of subjects: 64
Study 26649909 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline first followed by ACB
Number of subjects: 64
Study 26649909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 64
Study 26649909 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 25022831 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment (6 months of hospitalization on working days)
Number of subjects: 90
Study 25022831 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 90
Study 25022831 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory treatment (12 days of hospital visits over 6 months)
Number of subjects: 90
Study 22906138 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate Schools only
Number of subjects: 27
Study 22906138 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure only
Number of subjects: 27
Study 22906138 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP (Climate Schools and Preventure)
Number of subjects: 27
Study 22906138 — intervention group
Group type: COMPARATOR
Intervention: Control (alcohol, drug and health education as usual)
Number of subjects: 27
Study 20233850 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scheduled mammography)
Number of subjects: 3706
Study 17055227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 38
Study 17055227 — intervention group
Group type: COMPARATOR
Intervention: Enriched Supportive Therapy (Control)
Number of subjects: 38
Study 15867204 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab 375 mg/m² + CHOP)
Number of subjects: 399
Study 12641015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 283
Study 9705024 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP (750 mg/d)
Number of subjects: 25
Study 9705024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8539554 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher antigen content vaccine (20 micrograms pertussis toxoid and 20 micrograms filamentous hemagglutinin)
Number of subjects: 2050
Study 8539554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower antigen content vaccine (10 micrograms pertussis toxoid and 5 micrograms filamentous hemagglutinin)
Number of subjects: 2050
Study 8539554 — intervention group
Group type: COMPARATOR
Intervention: Both vaccine formulations
Number of subjects: 2050
Study 2181857 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-rubber balloon inflated with 400 mL for 1 month
Number of subjects: 10
Study 2181857 — intervention group
Group type: COMPARATOR
Intervention: Silicone-rubber balloon deflated for 1 month
Number of subjects: 10
Study 391622 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol nicotinate (Hexopal)
Number of subjects: 30
Study 31630916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided insertion (US)
Number of subjects: 100
Study 31630916 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmark insertion (LM)
Number of subjects: 100
Study 29283929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sets of 10 repetitions at 30% of 1 repetition maximum (1RM)
Number of subjects: 9
Study 29283929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sets of 5 repetitions at 70% of 1RM
Number of subjects: 9
Study 29283929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sets of 3 repetitions at 90% of 1RM
Number of subjects: 9
Study 27304455 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver reflections on asthma home and community management
Number of subjects: 13
Study 27304455 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 13
Study 25541015 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGFs)
Number of subjects: 15
Study 25541015 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRGFs)
Number of subjects: 15
Study 22973855 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning for five minutes
Number of subjects: 160
Study 22973855 — intervention group
Group type: COMPARATOR
Intervention: No interruption and no planning
Number of subjects: 160
Study 22973855 — intervention group
Group type: COMPARATOR
Intervention: Interruption but no planning
Number of subjects: 160
Study 22973855 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning but no interruption
Number of subjects: 160
Study 22973855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both planning and interruption
Number of subjects: 160
Study 21349484 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 2 days before PCI
Number of subjects: 200
Study 21349484 — intervention group
Group type: COMPARATOR
Intervention: Immediate PCI (Control group)
Number of subjects: 200
Study 21349484 — intervention group
Group type: COMPARATOR
Intervention: Registry group (long-term statin therapy)
Number of subjects: 200
Study 18834910 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT formulations
Number of subjects: 175
Study 18834910 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT formulation (specific formulation lower for serogroup A)
Number of subjects: 175
Study 18834910 — intervention group
Group type: COMPARATOR
Intervention: Licensed ACWY polysaccharide vaccine
Number of subjects: 175
Study 15719071 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07% high bioavailable, alcohol-free CPC rinse
Number of subjects: 55
Study 15719071 — intervention group
Group type: COMPARATOR
Intervention: Listerine Cool Mint containing essential oils
Number of subjects: 55
Study 15719071 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPC rinse
Number of subjects: 55
Study 12096085 — intervention group
Group type: EXPERIMENTAL
Intervention: Anethole dithiolethione (ADT) at 25 mg orally thrice daily for 6 months
Number of subjects: 112
Study 12096085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 12096085 — intervention group
Group type: EXPERIMENTAL
Intervention: Anethole dithiolethione (ADT)
Number of subjects: 112
Study 10625850 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride 0.15% oral mouthwash 3 times a day for 4 weeks
Number of subjects: 30
Study 10625850 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times a day for 4 weeks
Number of subjects: 30
Study 10625850 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 7793209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg orally)
Number of subjects: 123
Study 7793209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Codeine (800 mg ibuprofen + 60 mg codeine orally)
Number of subjects: 123
Study 7793209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 1942288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil 25 mg per day
Number of subjects: 10
Study 7024020 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) after 3 weeks of treatment
Number of subjects: 8
Study 7024020 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 8
Study 7024020 — intervention group
Group type: COMPARATOR
Intervention: Both CIT and CSII
Number of subjects: 8
Study 31284737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 7618
Study 31284737 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 7618
Study 28054436 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (60 mg)
Number of subjects: 95
Study 28054436 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soymilk powder)
Number of subjects: 95
Study 25726088 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 650
Study 25726088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study 25139268 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol in monosedation
Number of subjects: 307
Study 25139268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propofol + meperidine
Number of subjects: 307
Study 25139268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of midazolam + meperidine
Number of subjects: 307
Study 25139268 — intervention group
Group type: EXPERIMENTAL
Intervention: Other combinations
Number of subjects: 307
Study 25139268 — intervention group
Group type: COMPARATOR
Intervention: All sedation types
Number of subjects: 307
Study 22748356 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1710
Study 22748356 — intervention group
Group type: COMPARATOR
Intervention: eptifibatide
Number of subjects: 1710
Study 19773623 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT (tension-free vaginal tape)
Number of subjects: 264
Study 19773623 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O (tension-free vaginal tape obturator)
Number of subjects: 264
Study 17449994 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary tattoo of a pain intensity scale (TTPS)
Number of subjects: 111
Study 17449994 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the pain scale (PPS)
Number of subjects: 111
Study 14981104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic mastectomy
Number of subjects: 483
Study 14981104 — intervention group
Group type: COMPARATOR
Intervention: No bilateral prophylactic mastectomy (matched controls)
Number of subjects: 483
Study 14981104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic mastectomy with prior or concurrent bilateral prophylactic oophorectomy
Number of subjects: 483
Study 14981104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic mastectomy with intact ovaries
Number of subjects: 483
Study 11751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16
Study 11751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 16
Study 11751030 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 16
Study 11751030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10518867 — intervention group
Group type: EXPERIMENTAL
Intervention: Baking soda dentifrices with Zn++
Number of subjects: 11
Study 10518867 — intervention group
Group type: COMPARATOR
Intervention: Baking soda dentifrices (20% and 30%)
Number of subjects: 11
Study 10518867 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice containing 65% baking soda
Number of subjects: 11
Study 10518867 — intervention group
Group type: COMPARATOR
Intervention: Standard dentifrice containing 0.76% sodium monofluorophosphate
Number of subjects: 11
Study 10518867 — intervention group
Group type: EXPERIMENTAL
Intervention: Baking soda toothpastes
Number of subjects: 11
Study 7863474 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA ethyl esters (4 x 1 g capsules)
Number of subjects: 20
Study 7863474 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (4 x 1 g capsules, placebo)
Number of subjects: 20
Study 2491454 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg at night)
Number of subjects: 143
Study 2491454 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg at night)
Number of subjects: 143
Study 2491454 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 143
Study 2491454 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 143
Study 2491454 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine and Ranitidine
Number of subjects: 143
Study 60091 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 60091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30064718 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 1-7 mg/day; morning administration
Number of subjects: 0
Study 30064718 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 0
Study 30064718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25115324 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain placement
Number of subjects: 761
Study 25115324 — intervention group
Group type: COMPARATOR
Intervention: No drain placement
Number of subjects: 761
Study 23471362 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based interdisciplinary intervention for mothers
Number of subjects: 52
Study 21515017 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-ergometry training (n = 10)
Number of subjects: 28
Study 21515017 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (n = 10)
Number of subjects: 28
Study 21515017 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (n = 8)
Number of subjects: 28
Study 18373710 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 2 mg/kg weekly for 3 months
Number of subjects: 339
Study 18373710 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg weekly for up to 33 months
Number of subjects: 339
Study 18373710 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (dosage not specified) during the optional transition period
Number of subjects: 339
Study 17136942 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation containing essential vitamins plus quercetin (FRS)
Number of subjects: 11
Study 17136942 — intervention group
Group type: COMPARATOR
Intervention: Baseline time trial (B)
Number of subjects: 11
Study 12954742 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY infusion
Number of subjects: 24
Study 10823256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose subcutaneous LMWH Certoparin (8,000 anti-factor Xa U b.i.d.)
Number of subjects: 538
Study 10823256 — intervention group
Group type: COMPARATOR
Intervention: Adjusted dose intravenous UFH
Number of subjects: 538
Study 10823256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose subcutaneous LMWH Certoparin
Number of subjects: 538
Study 8965385 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 0
Study 8965385 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP
Number of subjects: 0
Study 8965385 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 1797193 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/m2 epirubicin weekly
Number of subjects: 40
Study 1797193 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/m2 epirubicin every 3 weeks
Number of subjects: 40
Study 6344649 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-steroid otic drops at the time of surgery and for 1 week afterward
Number of subjects: 107
Study 6344649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ampicillin for 24 hours preceding and 3 days following surgery
Number of subjects: 107
Study 6344649 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 107
Study 31982075 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg/day for 1 week, increasing to 50 mg/day for up to 12 months) plus usual care
Number of subjects: 114
Study 31982075 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus usual care
Number of subjects: 114
Study 30775982 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based interdisciplinary psychosocial intervention (7 sessions at home)
Number of subjects: 108
Study 30775982 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based interdisciplinary psychosocial intervention
Number of subjects: 108
Study 29221496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management involving monthly clinical reviews and individualised treatment support
Number of subjects: 398
Study 29221496 — intervention group
Group type: COMPARATOR
Intervention: Standard care following local pathways and NICE guidelines
Number of subjects: 398
Study 26022006 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 8399
Study 26022006 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study 24308806 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment without tailored feedback
Number of subjects: 178
Study 24308806 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment with tailored feedback
Number of subjects: 178
Study 24308806 — intervention group
Group type: COMPARATOR
Intervention: Generic information only
Number of subjects: 178
Study 22946768 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly pursed-lips breathing (PLB) reinforcement sessions via Skype for 4 weeks
Number of subjects: 22
Study 22946768 — intervention group
Group type: COMPARATOR
Intervention: Control group received PLB instruction at baseline only
Number of subjects: 22
Study 19341357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lecture and simulation
Number of subjects: 0
Study 19341357 — intervention group
Group type: COMPARATOR
Intervention: Lecture only (Control)
Number of subjects: 0
Study 17617281 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine/acetaminophen (C/A) 30/500 mg
Number of subjects: 121
Study 17617281 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen (H/A) 5/500 mg
Number of subjects: 121
Study 15339497 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianwei Yuyang Granules (JWYY group, n=30)
Number of subjects: 60
Study 15339497 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (control group, n=30)
Number of subjects: 60
Study 15339497 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (n=10)
Number of subjects: 60
Study 11757699 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy supported by autologous blood stem cell transplantation
Number of subjects: 0
Study 11757699 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized neuropsychological testing and quality-of-life assessment
Number of subjects: 0
Study 11757699 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy delay in complete responders to chemotherapy
Number of subjects: 0
Study 11408793 — intervention group
Group type: EXPERIMENTAL
Intervention: DA agonist (lisuride 0.2 mg)
Number of subjects: 36
Study 11408793 — intervention group
Group type: EXPERIMENTAL
Intervention: DA antagonist (fluphenazine 2 mg)
Number of subjects: 36
Study 9260011 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 10 micrograms.kg-1
Number of subjects: 100
Study 9260011 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20 micrograms.kg-1
Number of subjects: 100
Study 9260011 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms.kg-1
Number of subjects: 100
Study 9260011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9260011 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including neostigmine and placebo)
Number of subjects: 100
Study 8291866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy with doxorubicin (ADM)
Number of subjects: 0
Study 8291866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy with mitomycin C (MMC)
Number of subjects: 0
Study 8291866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical immunotherapy with bacillus Calmette-Guérin (BCG)
Number of subjects: 0
Study 8291866 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 0
Study 8291866 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant prophylactic instillation treatments (local cytostatics and immunoagents)
Number of subjects: 0
Study 3548315 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin and Doxorubicin (MA)
Number of subjects: 55
Study 3548315 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, Doxorubicin, and Cisplatin (MAP)
Number of subjects: 55
Study 29306990 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer navigation and education intervention
Number of subjects: 348
Study 29306990 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 348
Study 26729884 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonflict intervention encouraging public stance against conflict
Number of subjects: 24191
Study 26729884 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 24191
Study 25046667 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 25
Study 25046667 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 25
Study 25046667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ECTR and OCTR
Number of subjects: 25
Study 22471131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at starting and ending points of trapezius (Tianzhu (BL 10), Fengchi (GB 20), Quyuan (SI 13), Jugu (LI 16), Ashi)
Number of subjects: 60
Study 22471131 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at Jiaji (EX‐B 2) points
Number of subjects: 60